Emil J Freireich, DSc (Hon), MD

Department:
Leukemia

Research Interests:
Biology and natural history of and therapy for human leukemia

Research Summary:
My research focuses on studying the natural history of leukemia and evaluating therapies for the disease. I interact closely with my colleagues in the Department of Leukemia. I also collaborate with the Department of Hematopathology and faculty in the Department of Laboratory Medicine in assessing clinical pathologic findings of leukemia and studying leukocyte transfusion therapy for severe antibiotic resistant infection.

As Director of Special Medical Education Programs, I organize and supervise weekly Institutional Grand Rounds "Advances in Oncology," a weekly Core Curriculum course for all graduate medical trainees, and a Graduate Medical School curriculum for training in "Patient-Oriented Research," leading to M.S. and Ph.D. degrees.

Selected Publications:
Freireich EJ, Kurzrock R, Estrov Z. Metastasis--an alternative hypothesis. Cancer 103:1537-1539, 2005

Freireich EJ. The investigational new drug application--who benefits? Nat Clin Pract Oncol 3:62-63, 2006

Freireich EJ. Should terminally ill patients have the right to take drugs that pass phase I testing? Yes. BMJ 335:478, 2007

Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 110:3547-3551, 2007

Copyright 2009 The University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A. All rights reserved.